Poor
Not Aligned
Patient Risk:
Moderate
Summary
Partially aligns on cardiovascular risk reduction and bleeding risk with anticoagulants/antiplatelet agents, but includes multiple vitamin D–interaction claims and an ingredient composition claim (EPA/DHA content and 'omega-3 supplement/DHA') that are not supported by the provided label excerpts; overall substantial label misalignment.
Category Scores
Accurate Statements
Vascepa is used to reduce the risk of cardiovascular events.
Indications and usage: reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization; Clinical Studies REDUCE-IT shows risk reduction for primary and key secondary endpoints.
Vascepa may interact with blood thinners such as warfarin and increase the risk of bleeding.
5.3 Bleeding: bleeding incidence greater with concomitant antithrombotic medications such as warfarin; 7.1: monitor patients receiving VASCEPA with concomitant anticoagulants/antiplatelet agents for bleeding.
Unsupported Statements
Vascepa is a prescription-strength omega-3 supplement that contains EPA and DHA.
Provided label excerpts support EPA-related mechanism language but do not explicitly state omega-3 supplement status or that it contains DHA.
Vascepa is used to treat high triglycerides.
Label supports adjunct use to maximally tolerated statin therapy to reduce cardiovascular risk in patients with elevated TG meeting specific criteria, and adjunct to diet to reduce TG levels in severe hypertriglyceridemia; the general phrasing 'treat high triglycerides' is overbroad vs labeled population/conditions.
Vascepa is available by prescription only.
No dispensing/availability statement is present in the provided label excerpts.
Omega-3 fatty acids, including those in Vascepa, may decrease vitamin D levels by reducing the absorption of vitamin D from food and supplements.
No vitamin D content or absorption mechanism is present in the provided label excerpts.
Vascepa may increase the risk of bleeding when taken with vitamin D supplements.
Provided label excerpts discuss increased bleeding risk with concomitant antithrombotic medications, but do not mention vitamin D supplements.
Vitamin D supplements may also interact with blood thinners, although this is less well-studied.
No statement about vitamin D supplements interacting with blood thinners is present in the provided label excerpts.
There is limited data on the interaction between Vascepa and vitamin D supplements.
No vitamin D–interaction discussion is present in the provided label excerpts.
A study published in the Journal of Clinical Lipidology found that taking Vascepa with vitamin D supplements did not significantly affect the levels of either nutrient in the body.
No such study, journal reference, or nutrient-level findings are present in the provided label excerpts.
The study of Vascepa with vitamin D supplements was small and had limited power to detect potential interactions.
No such study size/power information is present in the provided label excerpts.
Patients taking both Vascepa and vitamin D supplements should be monitored for signs of bleeding or other adverse effects.
The label excerpts support monitoring with concomitant anticoagulants/antiplatelet agents, not vitamin D supplements specifically.
Contradictions
Important Omissions
VASCEPA prescribing is population- and condition-specific (e.g., adjunct to maximally tolerated statin therapy for elevated TG with established CVD or diabetes plus additional risk factors; adjunct to diet for severe hypertriglyceridemia) rather than a general 'high triglycerides' indication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Vitamin D–related interaction claims (including bleeding risk and monitoring tied to vitamin D supplements) are not supported by the provided label excerpts, which could mislead risk interpretation and monitoring focus; however, label-supported bleeding risk with anticoagulants/antiplatelet agents is correctly reflected.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple statements regarding vitamin D interactions and a claim about DHA content are not supported by the provided label excerpts; also 'treat high triglycerides' is overly general relative to labeled indications.
Suggested Improvement
Restrict claims to what the provided label excerpts support: cardiovascular risk reduction indication language, and increased bleeding risk/monitoring with concomitant anticoagulants/antiplatelet agents. Remove or qualify vitamin D–interaction and DHA/content claims unless supported by additional label sections not provided here.